These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 12747775)

  • 1. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
    Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of novel inhibitors of cyclin-dependent kinases.
    Kent LL; Hull-Campbell NE; Lau T; Wu JC; Thompson SA; Nori M
    Biochem Biophys Res Commun; 1999 Jul; 260(3):768-74. PubMed ID: 10403840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
    Al-awar RS; Ray JE; Hecker KA; Huang J; Waid PP; Shih C; Brooks HB; Spencer CD; Watkins SA; Patel BR; Stamm NB; Ogg CA; Schultz RM; Considine EL; Faul MM; Sullivan KA; Kolis SP; Grutsch JL; Joseph S
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3217-20. PubMed ID: 15149678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.
    Faul MM; Engler TA; Sullivan KA; Grutsch JL; Clayton MT; Martinelli MJ; Pawlak JM; LeTourneau M; Coffey DS; Pedersen SW; Kolis SP; Furness K; Malhotra S; Al-awar RS; Ray JE
    J Org Chem; 2004 Apr; 69(9):2967-75. PubMed ID: 15104433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors.
    Zhu G; Conner S; Zhou X; Shih C; Brooks HB; Considine E; Dempsey JA; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1231-5. PubMed ID: 12657252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
    Engler TA; Furness K; Malhotra S; Sanchez-Martinez C; Shih C; Xie W; Zhu G; Zhou X; Conner S; Faul MM; Sullivan KA; Kolis SP; Brooks HB; Patel B; Schultz RM; DeHahn TB; Kirmani K; Spencer CD; Watkins SA; Considine EL; Dempsey JA; Ogg CA; Stamm NB; Anderson BD; Campbell RM; Vasudevan V; Lytle ML
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2261-7. PubMed ID: 12824014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
    Sanchez-Martinez C; Shih C; Faul MM; Zhu G; Paal M; Somoza C; Li T; Kumrich CA; Winneroski LL; Xun Z; Brooks HB; Patel BK; Schultz RM; DeHahn TB; Spencer CD; Watkins SA; Considine E; Dempsey JA; Ogg CA; Campbell RM; Anderson BA; Wagner J
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3835-9. PubMed ID: 14552791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
    Mahale S; Aubry C; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
    Bioorg Chem; 2006 Oct; 34(5):287-97. PubMed ID: 16904725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.
    Zhu G; Conner SE; Zhou X; Chan HK; Shih C; Engler TA; Al-Awar RS; Brooks HB; Watkins SA; Spencer CD; Schultz RM; Dempsey JA; Considine EL; Patel BR; Ogg CA; Vasudevan V; Lytle ML
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3057-61. PubMed ID: 15149644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.
    Aubry C; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
    Chem Commun (Camb); 2004 Aug; (15):1696-7. PubMed ID: 15278142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
    Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
    Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
    Tsou HR; Otteng M; Tran T; Floyd MB; Reich M; Birnberg G; Kutterer K; Ayral-Kaloustian S; Ravi M; Nilakantan R; Grillo M; McGinnis JP; Rabindran SK
    J Med Chem; 2008 Jun; 51(12):3507-25. PubMed ID: 18494457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide.
    Panigone S; Debernardi S; Taya Y; Fontanella E; Airoldi R; Delia D
    Oncogene; 2000 Aug; 19(35):4035-41. PubMed ID: 10962560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
    Liang YC; Lin-Shiau SY; Chen CF; Lin JK
    J Cell Biochem; 1999 Oct; 75(1):1-12. PubMed ID: 10462699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides.
    Sanchez-Martinez C; Shih C; Zhu G; Li T; Brooks HB; Patel BK; Schultz RM; DeHahn TB; Spencer CD; Watkins SA; Ogg CA; Considine E; Dempsey JA; Zhang F
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3841-6. PubMed ID: 14552792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CaMK-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells.
    Morris TA; DeLorenzo RJ; Tombes RM
    Exp Cell Res; 1998 May; 240(2):218-27. PubMed ID: 9596994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
    Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.